Species |
Human |
Protein Construction |
CD20 (Ile141-Ser188) Accession # P11836 |
Poly-His |
Avi |
N-term |
|
C-term |
|
Purity |
> 95% as analyzed by SDS-PAGE |
Endotoxin Level |
≤ 1 EU/μg of protein by LAL method |
Biological Activity |
Immobilized Human CD20 at 1.0 μg/ml (100 μl/Well), dose response curve for rituximab with the EC50 of 0.8 μg/ml determined by ELISA. |
Expression System |
E. coli |
Apparent Molecular Weight |
~16.8 kDa, on SDS-PAGE under reducing conditions. |
Formulation |
Supplied as a 0.22 μm filtered solution in 20 mM PB, 10% glycerol, pH 7.0. |
Concentration |
Please refer to the COA for the specific lot. |
Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -70°C or below, the product can be stored for 2-3 weeks at 2-8°C or 3 months at -20°C. Avoid repeated freeze-thaw cycles. |

Immobilized Human CD20 at 1 μg/ml (100 μl/Well), dose response curve for rituximab with the EC50 of 0.8 μg/ml determined by ELISA.

Human CD20 Protein on SDS-PAGE under reducing conditions, the purity is greater than 95%.
Target Background |
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117 ) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. |
Synonyms |
MS4A1; CD20; MS4A-1; B-lymphocyte surface antigen B1; Bp35; Leukocyte surface antigen Leu-16; Membrane-spanning 4-domains subfamily A member 11 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
For more documents, please visit "Technical Support".